How Immunotherapies are Being Used for the Treatment of Mantle Cell Lymphoma
source: pixabay.com

How Immunotherapies are Being Used for the Treatment of Mantle Cell Lymphoma

Mantle cell lymphoma is a cancer that often responds well to initial treatment. Because of this, doctors often recommend intense treatment soon after diagnosis. While it is often successful, sometimes…

Continue Reading How Immunotherapies are Being Used for the Treatment of Mantle Cell Lymphoma

FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time
A Treatment for Mantle Cell Lymphoma gets Cleared Under FDA Accelerated Approval
source: pixabay.com

A Treatment for Mantle Cell Lymphoma gets Cleared Under FDA Accelerated Approval

According to a story from BioSpace, the biopharmaceutical company BeiGene Co., Ltd has recently announced that its drug zanubrutinib (marketed as BRUKINSA) has earned Accelerated Approval from the US Food…

Continue Reading A Treatment for Mantle Cell Lymphoma gets Cleared Under FDA Accelerated Approval

New Target Identified to Treat Acute Myeloid Leukemia and Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) and acute myeloid leukemia (AML) are two rare forms of blood cancer with a high unmet need. The majority of cases in these patient populations are…

Continue Reading New Target Identified to Treat Acute Myeloid Leukemia and Mantle Cell Lymphoma

Clinical Trial Results With Velcade in Mantle Cell Lymphoma Inspire Continued Research

According to a story from curetoday.com, a recent Phase 2 trial has demonstrated that bortezomib (marketed as Velcade) has the potential to be an effective therapy for patients with mantle…

Continue Reading Clinical Trial Results With Velcade in Mantle Cell Lymphoma Inspire Continued Research
A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients
Source: Pixabay.com

A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients

Mantle cell lymphoma is caused by a genetic mutation which  produces cancerous white blood cells. Of course, these are the cells which fight infection in a normal body. Therefore in…

Continue Reading A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients
Mantle Cell Lymphoma Patients in Western Australia Will Get Much Cheaper Access to Essential Treatment
PixelAnarchy / Pixabay

Mantle Cell Lymphoma Patients in Western Australia Will Get Much Cheaper Access to Essential Treatment

According to a story from news.com.au, patients in Western Australia will start getting much cheaper access to a highly valuable treatment next month for a rare form of cancer called…

Continue Reading Mantle Cell Lymphoma Patients in Western Australia Will Get Much Cheaper Access to Essential Treatment
Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients
source: pixabay.com

Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients

According to a story from adc.net.au, an innovative new cancer treatment regimen is responsible for doubling survival rates for patients with certain types of rare, difficult-to-treat blood cancers. This combination…

Continue Reading Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients
Novartis and Harvard Are Teaming up to Develop New Immunotherapy Technology
source: pixabay.com

Novartis and Harvard Are Teaming up to Develop New Immunotherapy Technology

According to a story from biopharmadive.com, the Swiss pharmaceutical company Novartis has entered a partnership with researchers from the engineering and applied sciences school at Harvard University. The team will…

Continue Reading Novartis and Harvard Are Teaming up to Develop New Immunotherapy Technology
Early Treatment is Essential for Fighting Back Against Relapsed Mantle Cell Lymphoma
Source: pixabay.com

Early Treatment is Essential for Fighting Back Against Relapsed Mantle Cell Lymphoma

According to a December 9th press release from Janssen Biotech, Inc, the results of a pooled analysis of patients with mantle cell lymphoma illustrated that those treated with Imbruvica (ibrutinib) had…

Continue Reading Early Treatment is Essential for Fighting Back Against Relapsed Mantle Cell Lymphoma
Close Menu